ChipDx Eyeing FDA Submission for Breast Cancer Relapse Test
May 03, 2011
ChipDx Eyeing FDA Submission for Breast Cancer Relapse Test
The firm has received pre-IDE evaluations from the FDA for BreastGeneDx and is currently looking for partners to help it during the next stage of assay validation.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.